4
Changes in Ownership
Nurix Therapeutics, Inc. Filed Acc 0001209191-23-026522
Chief Financial Officer sold 721 shares at $9.88 ($7,121)
- Chief Financial Officer acquired 2,886 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
van Houte Hans · Chief Financial Officer
Table I: Non-derivative
2 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2023-04-30 | Exercise or conversion : show line 1 in the form | +2,886 | 79,651 | D | ||
| 2023-05-01 | Sale : show line 2 in the form | −721 | $9.88 | $7,121 | 78,930 | D |
| Open-market sales · 721 sh · avg $9.88 · $7,121 | ||||||
Table II: Derivative
1 line| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2023-04-30 | Exercise or conversion : show line 3 in the form Restricted Stock Units | −2,886 | 31,747 | D |
Loading xslF345X04/doc4.xml…